Floatz logo

Cudc-907

High-grade Serous Ovarian Cancer

Curis, Inc.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

115 Active assets in the High-grade Serous Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Olaparib
Institute of Cancer Research, United Kingdom
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 2/3BB

View all 50 →

Same molecule, other indications

Cudc-907 is also rated in:

nut midline carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
brain neoplasmDormant
CC
Indicative ·
44 / 100
View asset →
neuroblastomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →